Bandaram Pharma Packtech Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 5, 2025, 7:32 pm

Competitors of Bandaram Pharma Packtech Ltd

All Competitor Stocks of Bandaram Pharma Packtech Ltd

Quarterly Result

Last Updated: August 19, 2025, 10:40 pm

Below is a detailed analysis of the quarterly data for Bandaram Pharma Packtech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 8.10 Cr.. The value appears to be declining and may need further review. It has decreased from 8.49 Cr. (Mar 2025) to 8.10 Cr., marking a decrease of 0.39 Cr..
• For Expenses, as of Jun 2025, the value is 7.47 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.95 Cr. (Mar 2025) to 7.47 Cr., marking a decrease of 0.48 Cr..
• For Operating Profit, as of Jun 2025, the value is 0.63 Cr.. The value appears strong and on an upward trend. It has increased from 0.54 Cr. (Mar 2025) to 0.63 Cr., marking an increase of 0.09 Cr..
• For OPM %, as of Jun 2025, the value is 7.78%. The value appears strong and on an upward trend. It has increased from 6.36% (Mar 2025) to 7.78%, marking an increase of 1.42%.
• For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.09 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.09 Cr..
• For Interest, as of Jun 2025, the value is 0.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from -0.10 Cr. (Mar 2025) to 0.46 Cr., marking an increase of 0.56 Cr..
• For Depreciation, as of Jun 2025, the value is 0.13 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.53 Cr. (Mar 2025) to 0.13 Cr., marking a decrease of 0.40 Cr..
• For Profit before tax, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.20 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.16 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00%.
• For Net Profit, as of Jun 2025, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.15 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.13 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.02. The value appears to be declining and may need further review. It has decreased from 0.12 (Mar 2025) to 0.02, marking a decrease of 0.10.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:49 am

Growth

Last Updated: September 5, 2025, 2:36 pm

Balance Sheet

Last Updated: December 4, 2025, 2:29 am

Below is a detailed analysis of the balance sheet data for Bandaram Pharma Packtech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00 Cr..
• For Reserves, as of Sep 2025, the value is 0.80 Cr.. The value appears strong and on an upward trend. It has increased from 0.65 Cr. (Mar 2025) to 0.80 Cr., marking an increase of 0.15 Cr..
• For Borrowings, as of Sep 2025, the value is 21.89 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 17.15 Cr. (Mar 2025) to 21.89 Cr., marking an increase of 4.74 Cr..
• For Other Liabilities, as of Sep 2025, the value is 5.67 Cr.. The value appears to be improving (decreasing). It has decreased from 9.12 Cr. (Mar 2025) to 5.67 Cr., marking a decrease of 3.45 Cr..
• For Total Liabilities, as of Sep 2025, the value is 40.36 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.92 Cr. (Mar 2025) to 40.36 Cr., marking an increase of 1.44 Cr..
• For Fixed Assets, as of Sep 2025, the value is 3.69 Cr.. The value appears to be declining and may need further review. It has decreased from 3.95 Cr. (Mar 2025) to 3.69 Cr., marking a decrease of 0.26 Cr..
• For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Investments, as of Sep 2025, the value is 1.40 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.40 Cr..
• For Other Assets, as of Sep 2025, the value is 35.27 Cr.. The value appears strong and on an upward trend. It has increased from 33.57 Cr. (Mar 2025) to 35.27 Cr., marking an increase of 1.70 Cr..
• For Total Assets, as of Sep 2025, the value is 40.36 Cr.. The value appears strong and on an upward trend. It has increased from 38.92 Cr. (Mar 2025) to 40.36 Cr., marking an increase of 1.44 Cr..

However, the Borrowings (21.89 Cr.) are higher than the Reserves (0.80 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Bandaram Pharma Packtech Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 5. It has increased from 0.81 (Mar 24) to 0.83, marking an increase of 0.02.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 5. It has increased from 0.81 (Mar 24) to 0.83, marking an increase of 0.02.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.65. This value is below the healthy minimum of 3. It has increased from 1.40 (Mar 24) to 1.65, marking an increase of 0.25.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.54. It has increased from 10.23 (Mar 24) to 10.54, marking an increase of 0.31.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.54. It has increased from 10.23 (Mar 24) to 10.54, marking an increase of 0.31.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 30.80. It has increased from 28.40 (Mar 24) to 30.80, marking an increase of 2.40.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 2.43. This value is within the healthy range. It has increased from 2.38 (Mar 24) to 2.43, marking an increase of 0.05.
• For PBIT / Share (Rs.), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 1.77 (Mar 24) to 1.61, marking a decrease of 0.16.
• For PBT / Share (Rs.), as of Mar 25, the value is 1.10. This value is within the healthy range. It has increased from 0.98 (Mar 24) to 1.10, marking an increase of 0.12.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 2. It has increased from 0.78 (Mar 24) to 0.82, marking an increase of 0.04.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 2. It has increased from 0.43 (Mar 24) to 0.82, marking an increase of 0.39.
• For PBDIT Margin (%), as of Mar 25, the value is 7.88. This value is below the healthy minimum of 10. It has decreased from 8.36 (Mar 24) to 7.88, marking a decrease of 0.48.
• For PBIT Margin (%), as of Mar 25, the value is 5.21. This value is below the healthy minimum of 10. It has decreased from 6.22 (Mar 24) to 5.21, marking a decrease of 1.01.
• For PBT Margin (%), as of Mar 25, the value is 3.56. This value is below the healthy minimum of 10. It has increased from 3.48 (Mar 24) to 3.56, marking an increase of 0.08.
• For Net Profit Margin (%), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 5. It has decreased from 2.78 (Mar 24) to 2.68, marking a decrease of 0.10.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 8. It has increased from 1.52 (Mar 24) to 2.68, marking an increase of 1.16.
• For Return on Networth / Equity (%), as of Mar 25, the value is 7.85. This value is below the healthy minimum of 15. It has increased from 4.24 (Mar 24) to 7.85, marking an increase of 3.61.
• For Return on Capital Employeed (%), as of Mar 25, the value is 7.75. This value is below the healthy minimum of 10. It has decreased from 10.69 (Mar 24) to 7.75, marking a decrease of 2.94.
• For Return On Assets (%), as of Mar 25, the value is 2.55. This value is below the healthy minimum of 5. It has increased from 1.62 (Mar 24) to 2.55, marking an increase of 0.93.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has increased from 0.38 (Mar 24) to 0.71, marking an increase of 0.33.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.36. This value exceeds the healthy maximum of 1. It has increased from 0.99 (Mar 24) to 1.36, marking an increase of 0.37.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.04. It has decreased from 1.30 (Mar 24) to 1.04, marking a decrease of 0.26.
• For Current Ratio (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.20, marking an increase of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.59, marking a decrease of 0.01.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.14. This value is within the healthy range. It has decreased from 6.56 (Mar 24) to 4.14, marking a decrease of 2.42.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 4.76. This value is within the healthy range. It has increased from 3.05 (Mar 24) to 4.76, marking an increase of 1.71.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.62. This value is below the healthy minimum of 3. It has increased from 2.01 (Mar 24) to 2.62, marking an increase of 0.61.
• For Enterprise Value (Cr.), as of Mar 25, the value is 75.85. It has increased from 59.42 (Mar 24) to 75.85, marking an increase of 16.43.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.05. This value is within the healthy range. It has increased from 1.74 (Mar 24) to 2.05, marking an increase of 0.31.
• For EV / EBITDA (X), as of Mar 25, the value is 26.01. This value exceeds the healthy maximum of 15. It has increased from 20.85 (Mar 24) to 26.01, marking an increase of 5.16.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.51, marking an increase of 0.21.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 4.40. This value exceeds the healthy maximum of 3. It has increased from 3.62 (Mar 24) to 4.40, marking an increase of 0.78.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.51, marking an increase of 0.21.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness